Clinical Trial

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with TMZ.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-16; most recent amendment 2026-07-23.
Status change: Not Yet Recruiting → Recruiting 2025-08-27
Trial Details
NCT Number NCT06931626
Lead Sponsor Nerviano Medical Sciences
Conditions Small Cell Lung Cancer
Enrollment 10 participants
Start Date 2025-08-15
Primary Completion 2026-10-30 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-24